Purpose Transcatheter aortic valve replacement (TAVR) is the standard treatment for patients with aortic diseases at high surgical risk. Transcatheter heart valve prostheses (THV) are inserted into the aortic valve, creating a new area between the native and artificial leaflets. This area, known as neo-sinus, increases the thrombogenicity of THVs. But there is a lack of testing methods that evaluate thrombogenicity in vitro. M...